Arsenal Biosciences, Inc.

Don’t miss our presentations at the CAR-TCR Summit Series tomorrow. We’re presenting on the development of our T cell therapy intended for metastatic castrate-resistant prostate cancer. We’ll also share insights on maintaining high potency evidenced by robust assays in our development of cell therapy products. https://bit.ly/3KBpuDJ Thanks to presenters Christopher Murriel and Haixia Wang. #CellTherapy #CancerResearch

It’s National Prostate Cancer Awareness Month, and we know patients have an urgent need for new, more effective treatments for metastatic prostate cancer. At ArsenalBio, we’re developing an autologous CAR-T cell therapy as a potential treatment for metastatic prostate cancer. We are rapidly advancing this program toward clinical studies and look forward to sharing updates. More about our prostate cancer program here: https://bit.ly/3VqLxzg #ProstateCancer #CancerResearch

For those attending the 4th Annual Process Development for Cell Therapies Summit in Boston this week, join ArsenalBio scientist Sophia Phillips for an informative case study presentation on Thursday, July 17, at 12:30pm ET. Sophia will discuss overcoming process development challenges in solid tumor-targeting cell therapies. Learn more: https://bit.ly/40mrRzr

On Tuesday, July 15, ArsenalBio scientist Max Lee will present during a workshop at the 4th Annual Process Development for Cell Therapies Summit being held in Boston. The session will explore implementing cutting-edge technology with phase-appropriate strategies. More: https://bit.ly/40agF90

Thanks to BiotechTV and Brad Loncar for sitting down with our CEO, Ken Drazan, M.D., to hear about the latest on our CAR T cell therapies specifically designed to overcome the challenges presented by solid tumors. Full video available here: https://bit.ly/46iJPqf

On Friday, Ken Drazan, M.D., ArsenalBio's CEO, will join a distinguished panel at the Society for Immunotherapy of Cancer (SITC)’s Biotech Strategic Meeting at the NYSE. The panel will cover cell therapy inflection points and strategies for reaching meaningful clinical and financial turning points — from capital efficiency to scientific value. More here: https://bit.ly/4nqwXVm

We’re honored to have Ken Drazan, MD, Co-founder, CEO, and Chairman of the Board, recognized as a winner in the EY Entrepreneur Of The Year® 2025 Bay Area program. For 40 years, EY US has celebrated ambitious entrepreneurs who are transforming industries, impacting communities, and creating long-term value. https://go.ey.com/4kI4eJI #EOYUS #EOYBAYAREA

Heading to Weights & Biases’ Fully Connected 2025? Be sure to hear from ArsenalBio’s Sofia Kyriazopoulou Panagiotopoulou as she presents “A T-cell foundation model for AI-powered target discovery and precision medicine” on June 18 (Track 3, 2:40pm PT). Learn how ArsenalBio’s automation lab and discovery platform enable large-scale data generation for training and validating AI models of T cells, a core cell type of the immune system with key roles in cancer, autoimmunity, and infection. View the full agenda: https://bit.ly/3FINBhW

At the American Society of Gene & Cell Therapy Annual Meeting this week? On Wednesday, don’t miss new research on our synthetic pathway activator (SPA) module and why it may enhance CAR-T cell therapy efficacy against solid tumors. Learn about our synthetic biology toolkit that empowers our programmable T cell therapies at https://bit.ly/3Sz1CBr. #ASGCT2025

At #ASGCT2025 this week? Don’t miss new research on our synthetic pathway activator (SPA) module and why it may enhance CAR-T cell therapy efficacy against solid tumors. #CellTherapy #ASGCT25 @ASGCTherapy